Parallel imports of pharmaceuticals has taken place in Denmark and the rest of the EU since the 1970s. In 2021, parallel imports accounted for 16% of turnover in the Danish market for medicinal products, an increase of 2% in comparison with 2018. Thanks to a favourable regulatory environment, savings in Denmark have also increased from DKK 610 million in 2018 to 740 DKK million in 2021.

Discover more details about the savings generated thanks to parallel import in the new study of Copenhagen Economics.